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The current dogma of G1 cell-cycle progression relies on growth factor-induced increase of cyclin
D:Cdk4/6 complex activity to partially inactivate pRb by phosphorylation and to sequester p27
Kip1-
triggering activation of cyclin E:Cdk2 complexes that further inactivate pRb. pRb oscillates between
an active, hypophosphorylated form associated with E2F transcription factors in early G1 phase and
an inactive, hyperphosphorylated form in late G1, S and G2/M phases. However, under constant
growthfactorstimulation,cellsshowconstitutivelyactivecyclinD:Cdk4/6throughoutthecellcycle
and thereby exclude cyclin D:Cdk4/6 inactivation of pRb. To address this paradox, we developed a
mathematical model of G1 progression using physiological expression and activity proﬁles from
synchronized cells exposed to constant growth factors and included a metabolically responsive,
activating modiﬁer of cyclin E:Cdk2. Our mathematical model accurately simulates G1 progression,
recapitulates observations from targeted gene deletion studies and serves as a foundation for
development of therapeutics targeting G1 cell-cycle progression.
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Introduction
Growth factor stimulation of G0 quiescent cells drives them
into the growth factor-dependent early G1 phase of the cell
cycle, followed by transition into the growth factor-indepen-
dent late G1 phase and progression into S phase (Ho and
Dowdy, 2002; Ortega et al, 2002; Sherr, 2004). This irreversible
commitment point, termed the restriction point (Pardee,
1974), is correlated with inactivation of the retinoblastoma
tumor suppressor protein (pRb) by hyperphosphorylation.
pRb, a negative regulator of G1-phase cell-cycle progression,
binds E2F transcription factors and chromatin remodeling
proteins (HDAC, Suv39, BRG1) to repress E2F target gene
expression (Ho and Dowdy, 2002; Ortega et al, 2002; Sherr,
2004). pRb is unphosphorylated and not bound to E2Fs in G0
quiescent cells. Growth factor stimulation of cells and
transition into early G1 results in hypophosphorylation of
pRb by cyclin:Cdk complexes that promote its assembly with
E2Fs(Ezhevskyetal,2001).Attherestrictionpoint,cyclin:Cdk
complexes inactivate pRb by hyperphosphorylation resulting
in E2F release and target gene induction. In both cycling
normal and tumor cells, pRb oscillates between an active,
hypophosphorylated form in early G1 and an inactive,
hyperphosphorylated form in late G1, S and G2/M phases
(Fang et al, 1996; Ezhevsky et al, 1997, 2001; Brugarolas et al,
1999; Nagahara et al, 1999; Stevaux and Dyson, 2002). Thus,
pRb is differentially regulated by two opposing cyclin:Cdk
complexes.
The current paradigm of G1 cell-cycle progression argues
that growth factor stimulation of quiescent cells results in the
gradual accumulation of active cyclin D:Cdk4/6 complexes
that perform at least two critical functions for cell-cycle
progression: (1) partial inactivation of pRb at the restriction
point, resulting in release of E2F transcription factors that
drive cyclin E expression, and (2) sequestration of the p27
Kip1
Cdk inhibitor (CKI), resulting in activation of cyclin E:Cdk2
complexes that complete pRb inactivation. However, recent
targeted gene deletions of G1-phase cyclins and Cdks in mice
have raised several concerns about the validity of this
paradigm (Pagano and Jackson, 2004; Sherr and Roberts,
2004). Moreover, similar to tumor cells growing in vivo, the
current paradigm remains largely untested in proliferating
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experimental data derived from highly synchronized cells
exposed to continuous growth factors, we developed a
mathematical model of G1 cell-cycle progression that accu-
rately simulates the observed physiological data, kinetics and
transitions. The model points to the presence of an unknown
activating ‘modiﬁer’ element that responds to metabolic input
to activate Cdk2 and potentially serves as a functional
analogue of the yeast G1-phase activator Bck2 (Newcomb
et al, 2003; Costanzo et al, 2004; de Bruin et al, 2004).
Results and discussion
To dissect regulation of G1 cell-cycle progression, we analyzed
human HCT116 colon carcinoma cells (RB
WT, p53
WT, p16
MUT)
grown under conditions of constant growth factor exposure.
HCT116 cells were synchronized in early G1 phase by density
arrest(contactinhibition)for48hinthepresenceofserumand
released from arrest by low-density replating. Synchronized
cells consistently entered S phase at 10h and G2/M phase by
18h (Figure 1A). This highly reproducible cell-cycle synchro-
nization method served as the basis for all subsequent
experiments.
We examined the expression and activity proﬁles of cell-
cycle regulatory proteins at various time points in the
synchronized HCT116 cells, which yielded several important
observations: (1) cyclin D1 and D2 were constitutively
expressed and cyclin D:Cdk4/6 complexes were constitutively
active from start to ﬁnish (0–27h) (Figure 1B). We did not
detectcyclinD3.(2)Incontrast,cyclinE:Cdk2complexeswere
present throughout the cell cycle, but oscillated between
inactivecomplexesinearlyG1andactivecomplexesinlateG1,
correlating with the inactivating, hyperphosphorylation of
pRb and p130 (Figure 1B). (3) pRb and p130 pocket proteins
were present in their active, hypophosphorylated forms in
early G1 phase (0–4h) and the inactive, hyperphosphorylated
forms ﬁrst appeared at 6h (Figure 1B). We did not detect
p107. (4) Consistent with hyperphosphorylated pRb/p130
being functionally inactive, the switch from hypo- to hyper-
phosphorylation of pRb/p130 correlated with expression of
bonaﬁdeE2Ftargetgenes,cyclinA2andDHFR(Figure1C),in
late G1. Similar proﬁles were obtained from S-phase-synchro-
nized arrested/released HCT116 cells (data not shown).
(5) Lastly, similar to G1-induced arrest by metabolic starvation
of glucose (Singh et al, 1999), deprivation of glutamine amino
acids results in an early G1 cell-cycle arrest typiﬁed by
continued cyclin D:Cdk4/6 activity, the presence of active
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Figure 1 Physiological expression and activity proﬁles of cell-cycle regulators during transition from early G1, across the restriction point, into late G1 and S phase.
Density-arrested (contact-inhibited) and released HCT116 cells were assayed for (A) kinase activity and immunoblot analysis, (B) mRNA levels by semi-quantitative
RT–PCR, (C) cyclin E:Cdk2 association by co-immunoprecipitation–immunoblot analysis, (D) released cells were plated into media containing glutamine (þGln) or
deprived of glutamine ( Gln) and assayed for cyclin E, Cdk2 and Cdk4 kinase activity and pRb immunoblot analysis; (E) Cdk2 and Cdk4/6 kinase activity and pRb
immunoblot following selective Cdk2 inhibition by roscovitine (15mM) at indicated time points. All studies were performed in triplicate with similar results; arrowhead
denotes slower migrating, inactive hyperphosphorylated pRb (panels B, D); panel D is derived from two regions of the same immunoblot.
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Thus, under constant growth factor conditions, we ﬁnd
constitutive cyclin D:Cdk4/6 activity, whereas cyclin E:Cdk2
and pRb activity oscillates during transition from early to late
G1 phase. These observations are consistent with results from
cycling human Tcells and cycling human primary ﬁbroblasts
(Ezhevsky et al, 2001). These observations combined with the
triple cyclin D and double Cdk4/6 genetic ablation studies
(Kozar et al, 2004; Malumbres et al, 2004) suggest that cyclin
D:Cdk4/6 activity is neither necessary nor sufﬁcient for
activation of cyclin E:Cdk2 complexes. Thus, the rate-limiting
activator of Cdk2 complexes at the restriction point remains
undeﬁned.
Several mathematical models have been developed that
provide insights into dynamical mechanisms of the cell cycle
under speciﬁc conditions (Aguda and Tang, 1999; Qu et al,
2003; Novak and Tyson, 2004). Novak and Tyson’s (2004)
model of the restriction point reproduces earlier experimental
results of cell-cycle progression in cycloheximide-treated
cells performed by Zetterberg and Larsson (1995). That
model as well as a model developed by Qu et al (2003) reﬂect
the current paradigm, which ultimately requires cyclin
E:Cdk2 complexes to oscillate in phase with inactivated
pRb. In both models, cyclin E:Cdk2 also acts as part of
a negative feedback loop promoting the degradation of its
inhibitor p27. Although these models reproduce central
features of G1 progression in mammalian cells, they do not
account for our experimental results of constitutively active
cyclin D and/or constitutive cyclin E expression throughout
G1 phase. Modiﬁcation of the Tyson model to constitutively
express cyclin E resulted in continued activation of cyclin
E:Cdk2 complexes and constant nonphysiological in
activation of pRb. A similar effect on pRb hyperphosphoryl-
ation was observed when p27 was eliminated from this
model. In contrast, p27 genetic deletions have no effect on the
timing of pRb inactivation (Pagano and Jackson, 2004; Sherr
and Roberts, 2004). Therefore, we surmised that the rate-
limiting mechanism governing Cdk2 activation requires
mechanisms distinct from those of positive feedback loops
and antagonistic interactions represented in these mathema-
tical models.
To quantitatively describe experimentally observed
dynamics of restriction point progression, we developed a
mathematical model of G1 progression that incorporates
additional regulation of Cdk2. For ease of interpretation, the
mathematical model is presented in diagrammatic cell
language (DCL) (Figure 2A) and in systems biology markup
language (see Supplementary information). The model dia-
gram includes interactions between some of the relevant
players in G1 cell-cycle progression, including cyclins, Cdks,
CKIs, pRb, E2F transcription factors, APC/C and Emi1
(Ezhevsky et al, 2001; Ho and Dowdy, 2002). Cdk4 represents
both Cdk4 and Cdk6, as both proteins have been shown to
have homologous functions in G1 progression and they are
activated when bound to cyclin D (D1, D2 or D3). Cyclin
D:Cdk4/6 complexes are inhibited by p16-INK4a family (not
present in HCT116 cells) and p27 family of proteins. Cyclin E
and cyclin A complexed with Cdk2 are also inhibited by p27
binding.
In formulating the model, we made select simpliﬁcations
to reduce the number of model parameters and focus on
modeling the biology relevant for ascertaining the potential
rate-limiting mechanism governing Cdk2 activation. Cdk2
and Cdk1 are present in an inhibited phosphorylated (Thr
14
and Tyr
15) state and require dephosphorylation by Cdc25A,
followed by Thr
160 or Thr
161 activating phosphorylation,
respectively, by CAK. We did not explicitly include these
kinasesandphosphatasesinourmathematicalmodelbecause,
beyond the requirement for Cdk activation, their role in
regulating G1 transition is not yet well deﬁned. As this model
concentrates on G1 progression, interactions involving APC/C
were also simpliﬁed (Vodermaier and Peters, 2002; Murray,
2004).
Parameter values of processes described in the model are
generally unknown in vivo, are cell-type-speciﬁc and can vary
over large ranges. Physiologically correct model output is
fairly robust to variations of parameters within those ranges.
Most parameter values are determined by ﬁtting to quantita-
tive data. To add additional constraints to the possible
solutions in parameter space that are consistent with the
quantitative data, we ﬁxed some parameter values to
physiological ranges found in the literature. Protein unbinding
rates were set to 0.1min
 1, which is of the same order of
magnitude as in other models of protein interaction. Turnover
for cyclins is rapid and was ﬁxed to 0.05min
 1 (half-life of
14min) (Maity et al, 1997; Carlson et al, 1999; Kahl and
Means, 2004). Concentrations of proteins in ‘ground’ states
were set to physiologically reasonable rates found in the
literature. Cdk levels were 100000molecules/cell (Arooz et al,
2000). Components such as pRb and APC/C have concentra-
tions lower than Cdks.
Cycling cells (normal and tumor) represent an oscillating
system in a constant environment that periodically resets
itself, requiring doubling of cellular mass and genome before
cytokinesis (Jorgensen and Tyers, 2004). Recent evidence
suggests that achieving an autonomous critical cell mass is
a prerequisite for cells to progress from G1 into S phase and
complete cell division (Dolznig et al, 2004; Jorgensen and
Tyers, 2004). Also, treatment of cells with cell-cycle inhibitors
does not slow down cellular growth, whereas inhibitors of
cellulargrowth inducecell-cyclearrest, suggestingthat growth
directly or indirectly regulates cell-cycle progression (Fingar
et al, 2002; Kim et al, 2002; Dutcher, 2004). In addition,
metabolic restriction experiments result in an early G1 cell-
cycle arrest containing active cyclin D:Cdk4/6 complexes,
active hypophosphorylated pRb and inactive cyclin E:Cdk2
complexes (Figure 1D; Singh et al, 1999). Moreover, the
analogous G1 regulatory pathway in yeast (START) contains a
metabolically regulated activator of G1 cell-cycle progression,
termed Bck2 (Newcomb et al, 2003; Costanzo et al, 2004;
de Bruin et al, 2004). Taken together, these observations led
us to introduce into our G1 progression model a ‘cell growth’
variable as an unspeciﬁed activating ‘modiﬁer’ of Cdk2
(Figure 2A).
The activating ‘modiﬁer’ is implemented as a switch, turned
on at the end of early G1 phase inducing a change in Cdk2
required for its activation, which is the simplest functional
interaction. Genetic ablation studies of cyclin E or Cdk2
demonstratethatprimaryandtumorcellsfailtoarrest(Berthet
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& 2007 EMBO and Nature Publishing Group Molecular Systems Biology 2007 3Figure 2 Dynamical model ofthe mammalian G1cell-cycle progression.(A)Themathematical modelis representedinthe DCL.Cdksand pRbare boxes,withcircles
inside denoting possible states. As an example we show the various Cdk2 states as vectors of integers (box read in the order of top to bottom and left to right). Proteins
withasingleinternalstatearerepresentedbyovals.Transitionsbetweenstatesarerepresentedbyﬁlledcirclesforbindingandunbinding,andbysquigglesthatcanalso
denote degradation of bound components or conformational change. The diagram describes Cdk4 and Cdk2 binding to p27. Cdk2 binds cyclin E or A, Cdk1 binds cyclin
A and Cdk2/1 can undergo a conformational change by the activating ‘modiﬁer’. pRb is hypo- to hyperphosphorylated by active forms of Cdk4 (light green) and Cdk2/
Cdk1 complexes, respectively (dark green). Hyperphosphorylated pRb unbinds E2F; E2F promotes the synthesis of cyclin E, A, Emi and itself. Cyclin A is degraded by
APC/CwhennotboundtoEmi.(B–E)Simulations(solidlines)ofthemodelﬁttodatafromsixrepresentativeparametersetsthatmeetthedeletioncriteria(dotswitherror
bars). Time zero refers to the synchronized entry of the cells into early G1.( B) Active Cdk2, total p27 and total cyclin E. (C) hyperphosphorylated E2F and pRb and
(D) total Emi and total cyclin A. (E) In silico prediction of Cdk2/1 inhibition: hyperphosphorylated pRb at 16h with respect to Cdk2/1 inhibition, normalized to control
(0% inhibition) for the population of six models that best ﬁt the data and meet the deletion criteria.
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contrast to previously published models of G1 progression in
mammalian cells, our mathematical model also incorporates
mechanisms to account for cyclin E or Cdk2 deletion.
Consistent with appropriate kinetic activation of cyclin
A:Cdk2/1 activation in cyclin E1/E2-deﬁcient cells (Kozar
etal,2004),cyclinA:Cdk2orcyclinA:Cdk1complexesarealso
activated by the ‘modiﬁer’, providing compensatory inactivat-
ing hyperphosphorylation of pRb.
Global parameter optimization techniques yielded an
ensemble of parameter sets that enabled our model to
quantitatively reproduce the data in Figure 1 (Figure 2B–E).
The result of an optimization run is an ensemble of 100
parameter sets that give the lowest cost function. To account
for cyclin E and Cdk2 genetic deletion experiments, we
examined each parameter set of the ensemble under the cyclin
E or Cdk2 deletion condition by setting the respective protein
synthesis rates to zero. The network is robust to variation in
mostoftheparametersunder thedeletioncondition. However,
owing to variations in the parameters for interactions where
cyclin A is involved, there are model solutions that do not
satisfy the deletion condition. Solutions were accepted for the
parameter sets for which cyclin A at 16h rose to at least 20%
of the activation level of the unperturbed simulation for each
deletion. Out of the 100 parameter sets, six fulﬁlled the
requirement of required cyclin A levels for these parameter
sets under the unperturbed condition, cyclin E deletion and
Cdk2 deletion (see Supplementary Figure 2). In addition, all
of these solutions showed no effect on pRb inactivation when
p27 was eliminated from the model (data not shown). This is
consistent with the activating ‘modiﬁer’ as an essential
regulator of Cdk2/1 activation in our model.
To test the ability of the model to predict the outcome of an
intervention, we examined the effect of Cdk2/1 inactivation.
Predictionof Cdk2/1 inhibitionwas accomplished by reducing
the association rates of Cdks to its substrates by a speciﬁed
percent fraction. The binding constant of the active Cdk
complexes with the substrate pRb, kb–E2—pRB, kb–A2—pRB
and kb–A1—pRB, were simultaneously reduced by different
amounts of inhibition. The model predicts that at greater than
80% inhibition of Cdk2/1, the fraction of active hypo-
phosphorylated pRb at 16h increases, whereas inactive
hyperphosphorylatedpRbdecreases(Figure2E).Theseresults
were consistent with validation experiments by acute Cdk2/1
inactivation with Roscovitine (Senderowicz, 2003; Figure 1E).
Roscovitine treatment of cells abolished Cdk2/1 activity
and pRb remained in its active, hypophosphorylated form.
In contrast, control cells contained active Cdk2/1 and
inactive, hyperphosphorylated pRb. At the low dose used here
(15mM), no alterations of Erk or cyclin D:Cdk4/6 activity were
detected (Figure 1E). Cyclin E:Cdk2 kinase activity peaks
during early S phase (Figure 1B). However, pRb becomes
hyperphosphorylated concomitant with the initial cyclin
E:Cdk2/1 activation at/near the restriction point, suggesting
that only a low level of cyclin E:Cdk2 activity is required to
completely inactivateacell’scomplement pRb(Figures1Band
2E). These data also effectively exclude the potential for the
modiﬁer to act on a speculated early G1-phase pRb phospha-
tase that would keep pRb in an active state. In that case, the
prediction would be that inactivation of downstream Cdk2/1
kinase activitywouldresultin hyperphosphorylated (inactive)
pRb, as the putative early G1 phosphatase would be
inactivated by the modiﬁer. However, the experimental data
in Figure 1E clearly show that Cdk2/1 inactivation maintains
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Figure 3 Model of G1 cell-cycle progression. Combining the physiological data (Figure 1) with results from the data-driven mathematical model (Figure 2), we propose
the following: growth factor stimulation of quiescent G0 cells activates cyclin D:Cdk4/6 complexes that hypophosphorylate both p130 and pRb resulting in E2F transition
fromp130toactive,hypophosphorylatedpRbinearlyG1.Continuedmitogenicsignalingresultsinincreasedcellulargrowthandaccumulationofmass,reachingacritical
threshold that activates the ‘modiﬁer’ leading to activation of pre-existing cyclin E:Cdk2 complexes, followed by pRb hyperphosphorylation (inactivation), release of E2F
transcription factors and induction of late G1/S-phase-speciﬁc genes and transition into late G1.
Mammalian G1 cell cycle progression
T Haberichter et al
& 2007 EMBO and Nature Publishing Group Molecular Systems Biology 2007 5pRb in the active state, and thereby excludes the involvement
of a speculative pRb phosphatase. Moreover, a pRb early G1
phosphatase is also without precedent in the literature. Thus,
our model accurately predicted the experimental outcome for
both complete Cdk2 inactivation and partial Cdk2 inhibition
(Figure 3).
Most current explanations of G1 cell-cycle progression are
based primarily on data generated from serum deprivation/
restimulation experiments and overexpression studies. In
serum restimulation experiments, cyclin D:Cdk4/6 activity
graduallyincreasesduringtheﬁrstearlyG1phase.However,in
proliferating cells, cyclin D:Cdk4/6 activity is essentially
constitutive in early and late G1 and S phases. In contrast,
pRb oscillates between the active, hypophosphorylated form
in early G1 and the inactive, hyperphosphorylated form in late
G1 and S phases of the cell-cycle phases (see Figure 1) (Fang
et al, 1996; Ezhevsky et al, 1997, 2001; Brugarolas et al, 1999;
Nagahara et al, 1999). The G1 cell-cycle paradigm will need to
be adjusted to account for these experimental observations.
Thus, either two completely independent regulatory networks
controlling G1 cell-cycle progression exist—one regulating
early G1 phase in cells coming from quiescence and another
regulating G1-phase transitions in cycling cells—or, there is a
common mechanism that regulates G1-phase progression that
has been overshadowed by the ramping up of cyclin D:Cdk4/6
activity observed at the beginning of early G1 phase in serum
restimulation experiments. The data-driven mathematical
approach (Christopher et al, 2004) presented here supports a
single, regulatory mechanism where cyclin E:Cdk2 activation
is independent of cyclin D:Cdk4/6. Our mathematical model is
in agreement with recent reports showing genetic ablation
of either all three D-type cyclins (Kozar et al, 2004) or their
cognate Cdk4/6 kinases (Malumbres et al, 2004) has limited
effect on the timing of cyclin E:Cdk2 activation. Importantly,
these reports also exclude p27
Kip1 sequestration by cyclin
D:Cdk4/6 complexes as the rate-limiting step forcyclin E:Cdk2
activation (Pagano and Jackson, 2004; Sherr and Roberts,
2004).
Inhibition of metabolic processes results in a G1 arrest
typiﬁed by continued active cyclin D:Cdk4/6 complexes,
active hypophosphorylated pRb and inactive cyclin E:CDk2
complexes, suggesting that metabolism plays a key, yet
undeﬁned role in G1 cell-cycle progression. Our mathematical
model is consistent with evidence linking cell growth with
regulation of proliferation (Tapon et al, 2001; Saucedo and
Edgar, 2002). It postulates the existence of an unspeciﬁed
activating ‘modiﬁer’ pathway that responds to cellular growth
and results in activation of cyclin E:Cdk2 complexes at the
restriction point allowing cells to progress through the cell
cycle. Consistent with the presence of an activating modiﬁer
element in the mammalian G1 cell cycle, the yeast G1 cell cycle
is positively regulated by both cyclin:cdk complexes
(Cln3:Cdc28) and an uncharacterized activator, Bck2 (New-
comb et al, 2003; Costanzo et al, 2004; de Bruin et al, 2004).
Bck2 is regulated by metabolic stimuli and genetically
functions below Cln3 (cyclin D homologue) and activates the
equivalent of cyclin E:Cdk2 complexes (Cln1/2:Cdc28) at the
yeast restriction point (START). Bck2 is a non-cyclin, non-Cdk
protein of unknown function that potentially allows for
metabolic activation of G1 cell-cycle progression. Unfortu-
nately, similar to the lack of homology between pRb and the
equivalent yeast transcription factor repressor, Whi5, a
metazoan Bck2 homologue has not yet been identiﬁed.
Elucidating the biochemical mechanism of Cdk2 activation
and ascertaining the identity of the activating ‘modiﬁer’
proposed here is an important step in investigating the effects
of therapeutics targeting G1 cell-cycle progression to advance
drug development.
Materials and methods
Cell culture and cell-cycle synchronization
Human HCT116 colon carcinoma cells (ATCC) were grown in DMEM
(Life Technologies), 5% FBS (Sigma) and antibiotics, at 371C. Cells
were density-arrested by plating at 5 10
5cells/cm
2 for 48h in 5%
FBS, trypsinized and replated at low density (1 10
5cells/cm
2). Cell-
cycle progression was assayed by using propidium iodide FACS. Cells
were treated with 15mM roscovitine (EMD Biosciences) at replating.
Immunoblotting, immunoprecipitation and kinase
assays
Immunoblotswereperformedusinganti-cyclinE(HE12),anti-cyclinA
(H432), anti-cyclin D (H295), Cdk2 (M20 and D12), anti-p27 (C19),
anti-actin (I19), anti-p130 (C-20) (Santa Cruz Biotech) and anti-pRb
(554136; BD Biosciences) antibodies. Immunoprecipitations were
performed using anti-Cdk6 (C-21), anti-Cdk4 (C-22) and anti-Cdk2
(M20)antibodies(SantaCruz).Immunoprecipitation–kinasereactions
were performed using GST-pRb as a substrate for Cdk4/6 and histone
H1 (Sigma) for Cdk2.
Reverse transcriptase–PCR
RNA was puriﬁed (Qiagen), and RT–PCR was performed (Qiagen)
using the following primers:
cyclin A2 (GGCCGAAGACGAGACGGGTTGCACC),
(CAGGCCAGCTTTGTCCCGTGAC);
DHFR (ATGCCTTTCTCCTCCTGG), (CGCTAAACTGCATCGTCGC);
and
b-actin (TGAACCCCAAGGCCAACCGCGAGAA), (AAGCAGCCGTG
GCCATCTCTTG);
cyclin D1 (GCCTGAACCTGAGGAGCCCC), (GTCTAAGTCAGAGATG
GAAGG);
cyclin E1 (TAAAGTGGCGTTTAAGTCCCC), (ATCTTCATCAGCGA
CGCC).
Numerical simulations and parameter optimization
Simulation and parameter estimation were performed with a custom
software written in Cþþ(Press et al, 1992; Maimon and Browning,
2001) on a clusterof 16 Linuxcomputers, each containing two 2.0GHz
Intel
s Xeont processors. The software converted the diagram in
Figure2intoalistofreactionsbetweenmodelcomponentsandcreated
asystemofcoupleddifferentialequationsforconcentrationsofprotein
species. Differential equations were solved using CVODE (Cohen and
Hindmarsh, 1996). For parameter estimation, we used a differential
evolution algorithm (Storn, 1999). The algorithm maintains a
population of parameter sets while minimizing the cost function. At
each iteration, population members with intolerably high costs are
discarded, and new ones are created on the basis of lower cost. At the
end of an optimization run, an ensemble of parametersets with lowest
costs was stored for further analysis and simulations (Supplementary
information).
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Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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